- Home
- NBTX vs LXRX Comparison
NBTX vs LXRX Comparison
Compare NBTX & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- LXRX
- Stock Information
- Founded
- NBTX 2003
- LXRX 1995
- Country
- NBTX France
- LXRX United States
- Employees
- NBTX N/A
- LXRX N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- LXRX Health Care
- Exchange
- NBTX Nasdaq
- LXRX Nasdaq
- Market Cap
- NBTX 211.9M
- LXRX 228.8M
- IPO Year
- NBTX 2020
- LXRX 2000
- Fundamental
- Price
- NBTX $4.57
- LXRX $0.89
- Analyst Decision
- NBTX Strong Buy
- LXRX Buy
- Analyst Count
- NBTX 1
- LXRX 4
- Target Price
- NBTX $8.00
- LXRX $3.67
- AVG Volume (30 Days)
- NBTX 7.1K
- LXRX 5.3M
- Earning Date
- NBTX 04-02-2025
- LXRX 07-31-2025
- Dividend Yield
- NBTX N/A
- LXRX N/A
- EPS Growth
- NBTX N/A
- LXRX N/A
- EPS
- NBTX N/A
- LXRX N/A
- Revenue
- NBTX N/A
- LXRX $31,213,000.00
- Revenue This Year
- NBTX N/A
- LXRX N/A
- Revenue Next Year
- NBTX $221.06
- LXRX N/A
- P/E Ratio
- NBTX N/A
- LXRX N/A
- Revenue Growth
- NBTX N/A
- LXRX 1251.21
- 52 Week Low
- NBTX $2.76
- LXRX $0.28
- 52 Week High
- NBTX $6.00
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- NBTX 52.43
- LXRX 63.27
- Support Level
- NBTX $4.31
- LXRX $0.80
- Resistance Level
- NBTX $5.00
- LXRX $0.96
- Average True Range (ATR)
- NBTX 0.26
- LXRX 0.07
- MACD
- NBTX -0.06
- LXRX 0.02
- Stochastic Oscillator
- NBTX 24.44
- LXRX 81.52
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.